AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
The emergence of new infections in India is a growing concern
This two-day program was attended by 40 doctors & paramedical staff
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated